Cyclin E expression and prognosis in breast cancer patients: A meta-analysis of published studies

被引：39

作者：

Wang, Lei

Shao, Zhi-Ming

机构：

[1] Fudan Univ, Dept Oncol, Dept Breast Surg, Canc Hosp,Canc Inst, Shanghai 200032, Peoples R China

[2] Shandong Acad Med Sci, Dept Breast Surg, Shandong Canc Hosp, Jinan, Peoples R China

来源：

CANCER INVESTIGATION | 2006年 / 24卷 / 06期

基金：

中国国家自然科学基金;

关键词：

breast cancer; cyclin; prognosis;

D O I：

10.1080/07357900600894799

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In vitro studies showed that cyclin E can accelerate the cell cycle by shorten the G1/S phase transition. Therefore, varieties of studies have investigated the relationship between cyclin E and survival in breast cancer patients. However, the results differed widely between studies. We reviewed the published studies and performed a meta-analysis, which including 12 independent studies and 2,534 patients. The combined HR estimate for relapse-free survival (RFS) was 2.32 (95% CI, 1.25-4.30) and 1.72 (95% CI, 0.95-3.10) in univariate and multivariate analysis, respectively. In addition, the combined HR estimate for overall survival (OS) and breast cancer specific survival (BCSS) was 2.98 (95% CI, 1.85-4.78) and 2.86 (95% CI, 1.85-4.41) in univariate and multivariate analysis, respectively. In conclusion, the high level of cyclin E appears to be an independent prognostic factor to OS/BCSS of breast cancer patients but not to RFS.

引用

页码：581 / 587

页数：7

共 37 条

[1]

Abe O, 1998, LANCET, V352, P930

[2] Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p2l, p27, and antiestrogens in breast cancer [J].